Arrowstreet Capital Limited Partnership raised its holdings in Celgene Co. (NASDAQ:CELG) by 1,489.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,907,052 shares of the biopharmaceutical company’s stock after acquiring an additional 1,787,052 shares during the quarter. Arrowstreet Capital Limited Partnership owned 0.24% of Celgene worth $247,669,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors also recently bought and sold shares of CELG. Janus Henderson Group PLC raised its holdings in Celgene by 4,290.5% during the 2nd quarter. Janus Henderson Group PLC now owns 8,408,961 shares of the biopharmaceutical company’s stock worth $1,092,071,000 after buying an additional 8,217,433 shares during the period. BlackRock Inc. raised its holdings in Celgene by 5.7% during the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after buying an additional 3,084,227 shares during the period. Oaktop Capital Management II L.P. acquired a new stake in Celgene during the 2nd quarter worth about $271,605,000. Vanguard Group Inc. raised its holdings in Celgene by 3.1% during the 2nd quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock worth $6,951,579,000 after buying an additional 1,610,056 shares during the period. Finally, Harbour Capital Advisors LLC increased its holdings in shares of Celgene by 12,913.6% in the 2nd quarter. Harbour Capital Advisors LLC now owns 1,587,271 shares of the biopharmaceutical company’s stock valued at $12,222,000 after purchasing an additional 1,575,074 shares during the period. Hedge funds and other institutional investors own 80.17% of the company’s stock.
A number of equities analysts have recently weighed in on the company. William Blair reiterated an “outperform” rating on shares of Celgene in a report on Friday, October 20th. Leerink Swann reiterated a “buy” rating and issued a $156.00 target price on shares of Celgene in a report on Friday, October 20th. Piper Jaffray Companies reiterated a “neutral” rating and issued a $133.00 target price on shares of Celgene in a report on Monday, October 23rd. Wells Fargo & Company downgraded Celgene from an “outperform” rating to a “market perform” rating in a report on Thursday, October 26th. Finally, Vetr downgraded Celgene from a “buy” rating to a “hold” rating and set a $145.17 target price on the stock. in a report on Wednesday, September 6th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, twenty have issued a buy rating and two have assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $139.57.
Celgene Co. (CELG) opened at $106.09 on Friday. Celgene Co. has a twelve month low of $94.55 and a twelve month high of $147.17. The company has a market capitalization of $80,881.07, a P/E ratio of 16.05, a P/E/G ratio of 0.79 and a beta of 1.78. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31.
Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping analysts’ consensus estimates of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The firm had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter in the prior year, the company posted $1.58 earnings per share. The firm’s revenue was up 10.2% on a year-over-year basis. analysts expect that Celgene Co. will post 6.67 EPS for the current fiscal year.
In other Celgene news, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the sale, the insider now owns 3,925 shares of the company’s stock, valued at $564,768.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gilla Kaplan sold 9,250 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total value of $1,309,430.00. Following the sale, the director now directly owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The disclosure for this sale can be found here. Corporate insiders own 0.95% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/10/celgene-co-celg-shares-bought-by-arrowstreet-capital-limited-partnership.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related companies with MarketBeat.com's FREE daily email newsletter.